Abstract: The techniques and systems described herein relate to manufacturing, characterizing, and/or identifying one or more types of magnetic nanowires (MNWs). One or more types of MNWs may be associated with different objects, and a system may identify the objects based on the magnetic nanowires associated with the objects. For example, such techniques may involve characterizing the types of MNWs based on magnetic field transmission characteristics and ferromagnetic resonance characteristics of each type of MNW. In some examples, the techniques described herein may enable the identification of each of a plurality of types of MNWs present in a sample or object based on a combined transmission value of the sample. Such techniques may enable the development and use of barcode-like systems of different types of MNWs for labeling and identifying objects of interest.

Abstract: This disclosure describes example techniques and systems for identifying the presence and/or composition of nucleic acids in the blood of a host organism of a model species harboring tissue of a donor organism of another species. For example, the technique may involve identifying the presence and composition of nucleic acids in the blood of a mouse harboring tissue of a human or another companion animal. These cell-free nucleic acids that are identified can be used as biomarkers to determine the presence of a disease, its biological behavior, its rate of progression, and/or the response of the disease to one or more unique therapies. In other examples, the cell-free nucleic acids may be used as biomarkers to determine a response of the host species to the tissue of the donor organism or a response of tissue derived from the second organism to transplantation within the first organism of the first species.

Abstract: The techniques and systems described herein relate to manufacturing, characterizing, and/or identifying one or more types of magnetic nanowires (MNWs). One or more types of MNWs may be associated with different objects, and a system may identify the objects based on the magnetic nanowires associated with the objects. For example, such techniques may involve characterizing the types of MNWs based on magnetic field transmission characteristics and ferromagnetic resonance characteristics of each type of MNW. In some examples, the techniques described herein may enable the identification of each of a plurality of types of MNWs present in a sample or object based on a combined transmission value of the sample. Such techniques may enable the development and use of barcode-like systems of different types of MNWs for labeling and identifying objects of interest.

Abstract: This disclosure describes example techniques and systems for identifying the presence and/or composition of nucleic acids in the blood of a host organism of a model species harboring tissue of a donor organism of another species. For example, the technique may involve identifying the presence and composition of nucleic acids in the blood of a mouse harboring tissue of a human or another companion animal. These cell-free nucleic acids that are identified can be used as biomarkers to determine the presence of a disease, its biological behavior, its rate of progression, and/or the response of the disease to one or more unique therapies. In other examples, the cell-free nucleic acids may be used as biomarkers to determine a response of the host species to the tissue of the donor organism or a response of tissue derived from the second organism to transplantation within the first organism of the first species.

Abstract: Systems, devices, and techniques are described for characterizing subjects, such as dogs or humans, into risk categories using a blood test. For example, a method includes marking a plurality of cells from a blood sample of a subject with antibodies that recognize a plurality of markers comprising at least two of ?v?3-integrin, hematopoietic progenitor marker CD34, hematopoietic progenitor marker CD117, hyaluronic acid receptor CD44, or panleukocyte marker CD45 and obtaining, based on expression of the plurality of markers in the plurality of cells, a plurality of data features for the plurality of cells. The method may also include applying a plurality of trained analytical models to a subset of the plurality of data features and generating, based on the trained analytical models, one classification for the blood sample, wherein the classification is selected from at least a high risk of HSA and a low risk of HSA.

Abstract: The techniques and systems described herein relate to manufacturing, characterizing, and/or identifying one or more types of magnetic nanowires (MNWs). One or more types of MNWs may be associated with different objects, and a system may identify the objects based on the magnetic nanowires associated with the objects. For example, such techniques may involve characterizing the types of MNWs based on magnetic field transmission characteristics and ferromagnetic resonance characteristics of each type of MNW. In some examples, the techniques described herein may enable the identification of each of a plurality of types of MNWs present in a sample or object based on a combined transmission value of the sample. Such techniques may enable the development and use of barcode-like systems of different types of MNWs for labeling and identifying objects of interest.

Abstract: The techniques and systems described herein relate to using machine learning models to associate a known biological state of an organism with patterns of expression exhibited by the organism of genes of a gene signature associated with a disease state, such as to train the machine learning models to determine unknown biological states associated with the patterns of expression. Some techniques include determining an unknown biological status of an organism based on an expression pattern of genes of a gene signature in the organism, which the machine learning model may compare to known expression patients learned during the training technique. The expression patterns may be determined based on sequences of exosomal RNAs isolated from exosomes from a sample of bodily fluid from the organism and an approximate number of times each RNA sequence that substantially aligns with a gene of the gene signature occurs in the sample of bodily fluid.

Abstract: In certain embodiments, the present invention provides a method of treating a subject having a tumor that expresses EGFR and/or uPAR, even if at low levels. In certain embodiments, the present invention provides a method of preventing hemangiosarcoma (HSA) in a dog predisposed to developing HSA or angiosarcoma in a human predisposed to developing angiosarcoma. In certain embodiments, the present invention provides a method of preventing a hemangiosarcoma (HSA) in a dog that is positive for HSA by means of a blood test but negative by tumor imaging.

Abstract: The techniques and systems described herein relate to manufacturing, characterizing, and/or identifying one or more types of magnetic nanowires (MNWs). One or more types of MNWs may be associated with different objects, and a system may identify the objects based on the magnetic nanowires associated with the objects. For example, such techniques may involve characterizing the types of MNWs based on magnetic field transmission characteristics and ferromagnetic resonance characteristics of each type of MNW. In some examples, the techniques described herein may enable the identification of each of a plurality of types of MNWs present in a sample or object based on a combined transmission value of the sample. Such techniques may enable the development and use of barcode-like systems of different types of MNWs for labeling and identifying objects of interest.

Abstract: This disclosure describes example techniques and systems for identifying the presence and/or composition of nucleic acids in the blood of a host organism of a model species harboring tissue of a donor organism of another species. For example, the technique may involve identifying the presence and composition of nucleic acids in the blood of a mouse harboring tissue of a human or another companion animal. These cell-free nucleic acids that are identified can be used as biomarkers to determine the presence of a disease, its biological behavior, its rate of progression, and/or the response of the disease to one or more unique therapies. In other examples, the cell-free nucleic acids may be used as biomarkers to determine a response of the host species to the tissue of the donor organism or a response of tissue derived from the second organism to transplantation within the first organism of the first species.

Abstract: A method for detecting aggressive tumor behavior and/or increased risk for tumor metastasis generally includes analyzing a tumor sample from the subject for expression of transcripts from coding regions of the cell cycle gene cluster, the immune-1 gene cluster, or the immune-2 gene cluster; computing a sum of log2-transformed mean-centered expression values, thereby generating a Gene Cluster Expression Summary Score (GCESS) for the sample; and detecting a tumor with aggressive behavior and/or increased risk for tumor metastasis. An aggressive tumor and/or increased risk for tumor metastasis may be indicated where the cell cycle gene cluster is analyzed and the sample GCESS is greater than 0, or the immune-1 gene cluster or the immune-2 gene cluster is analyzed and the sample GCESS is less than 0.

Abstract: In certain embodiments, the present invention provides a method of treating a subject having a tumor that expresses EGFR and/or uPAR, even if at low levels. In certain embodiments, the present invention provides a method of preventing hemangiosarcoma (HSA) in a dog predisposed to developing HSA or angiosarcoma in a human predisposed to developing angiosarcoma. In certain embodiments, the present invention provides a method of preventing a hemangiosarcoma (HSA) in a dog that is positive for HSA by means of a blood test but negative by tumor imaging.

Abstract: A variety of methods, compositions and kits are provided for the early detection, diagnosis and treatment of hemangiosarcoma in dogs and angiosarcomas in humans.